SIRPA and metastatic melanoma: Given that high expression of checkpoints PD-1, PD-L1, VISTA, SIRPα, and CD47 expression associated with anti-PD-1 response in our cohort, it remains to be investigated whether combination therapy with myeloid checkpoint blockade can overcome anti-PD-1 resistance in metastatic melanoma.